Treatment of autoimmune hepatitis: Current and future therapies

Current Treatment Options in Gastroenterology

Volumn 7, Issue 5, 2004, Pages 413-420

  Alvarez, Fernando ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AZATHIOPRINE; BUDESONIDE; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 2D6; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; HLA DR1 ANTIGEN; INSULIN; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MERCAPTOPURINE; METHOTREXATE; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; RIFAMPICIN; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ACNE; ADRENAL SUPPRESSION; ANEMIA; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; BONE DISEASE; BONE MARROW SUPPRESSION; CATARACT; CLINICAL FEATURE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; EARLY DIAGNOSIS; ENTERITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; GLUCOSE INTOLERANCE; HIRSUTISM; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INTRAHEPATIC CHOLESTASIS; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MECHANICS; MONOTHERAPY; MOOD DISORDER; MOON FACE; NAUSEA; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PROGNOSIS; REVIEW; SIDE EFFECT; STRIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR;

EID: 7944222306     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0054-9     Document Type: Review

References (46)

1. Alvarez F, Berg PA, Bianchi FB, et al.: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31: 29-938.
2. Maggiore G, Veber F, Bernard O, et al.: Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993, 17: 76-381.
3. Gregorio GV, Portmann B, Reid F, et al.: Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
4. Maggiore G, Porta G, Bernard O, et al.: Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990, 116:280-282.
5. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F: Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997, 27:578-582.
6. Homberg JC, Abuaf N, Bernard O, et al.: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987, 7:1333-1339.
7. Manns MP, Kruger M: Immunogenetics of chronic liver diseases. Gastroenterology 1994, 106:1676-1697.
8. Marcos Y, Fainboim HA, Capucchio M, et al.: Two-locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis Hepatology 1994, 19:1371-1374.
9. Vazquez-Garcia MN, Alaez C, Olivo A, et al.: MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998, 28:985-990.
10. Seki T, Ota M, Furuta S, et al.: HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients Gastroenterology 1992, 103:1041-1047.
11. Czaja AJ, Kruger M, Santrach PI, et al.: Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997, 92:2197-2200.
12. Czaja AJ: Natural history clinical features, and treatment of autoimmune hepatitis. Semim Liver Dis 1984, 4:1-12.
13. Djilali-Saiah I, Renous R, Caillat-Zucman S, et al.: Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004, (in press).
14. Yamamoto AM, Mura C, Lemos-Chiarandini C, et al.: Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes. Clin Exp Immunol 1993, 92:381-390.
15. Loeper J, Descatoire V, Maurice M, et al.: Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993, 104: 03-216.
16. Muratori L, Parola M, Ripalti A, et al.: Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000, 46:553-561.
17. Hajoui O, Martin S, Alvarez F: Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies. Clin Exp Immunol 1998, 113:339-345.
18. Wen L, Peakman M, Lobo-Yeo A, et al.: T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis Lancet 1990, 336:1527-1530.
19. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F: DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol 2002, 169:4889-4896.
20. Cook GC, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971, 40:159-185.
21. Soloway RD, Summerskill WH, Baggenstoss AH, et al.: Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972, 63:820-833.
22. Roberts SK, Therneau TM, Czaja AJ: Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996, 110:848-857.
23. Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973, 1:735-737.
24. Hyams JS, Ballow M, Leichtner AM: Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987, 93:890-893.
25. Jackson LD, Song E: Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995, 36:459-461.
26. Debray D, Maggiore G, Girardet JP, et al.: Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999, 135:111-114.
27. Alvarez F, Ciocca M, Canero-Velasco C, et al.: Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999, 30:222-227.
28. Danielsson A, Prytz H: Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994, 8:585-590.
29. Lennard L: The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 1992, 43:329-339.
30. Rivard GE, Lin KT, Leclerc JM, David M: Milk could decrease the bioavailability of 6-mercaptopurine. Am J Pediatr Hematol Oncol 1989, 11:402-406.
31. Johnson PJ, McFarlane IG, Williams R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995, 333:958-963.
32. Pratt DS, Flavin DP, Kaplan MM: The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996, 110:271-274.
33. Ziegler TR, Fernandez-Estivariz C, Gu LH, et al.: Severe villus atrophy and chronic malabsorption induced by azathioprine Gastroenterology 2003, 124:1950-1957.
34. Perreaux F, Zenaty D, Capron F, et al.: Azathioprine-induced lung toxicity and efficacy of cyclosporin A in a young girl with type 2 autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2000, 31:190-192.
35. Paradis K, al Edreesi M, St Vil D, et al.: Cyclosporine kinetics in pediatric liver transplant recipients: impact of dose fractionation on true glomerular filtration rate. Transplant Proc 1994, 26:2777-2778.
36. Van Thiel DH, Wright H, Carroll P, et al.: Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:771-776.
37. Burak KW, Urbanski SJ, Swain MG: Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998, 29:990-993.
38. Kanzler S, Gerken G, Dienes HP, et al.: Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Gastroenterol 1997, 35: 71-578.
39. Richardson PD, James PD, Ryder SD: Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000, 33:371-375.
40. Hegarty JE, Nouri Aria KT, Portmann B, et al.: Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983, 3:685-689.
41. Kanzler S, Gerken G, Lohr H, et al.: Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001, 34:354-355.
42. Zhang X, Izikson L, Liu L, Weiner HL: Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001, 167:4245-4253.
43. Wrenshall LE, Ansite JD, Eckman PM, et al.: Modulation of immune responses after portal venous injection of antigen Transplantation 2001, 71:841-850.
44. Alegre ML, Peterson LJ, Xu D, et al.: A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994, 57:1537-1543.
45. Herold KC, Hagopian W, Auger JA, et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
46. Fleischmann R, Shealy D: Developing a new generation of TNF{alpha} antagonists for the treatment of rheumatoid arthritis. Mol Intervent 2003, 3:310-318.